RSLV-132

N/A

Report date: 2023/12/25 15:09:37
First In Class

Base Information

Drug NameRSLV-132
Drug Alias NameRNase-Fc fusion proteinRSLV-132
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionRNA inhibitors
TargetsRibonucleic Acid
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Lupus Erythematosus, SystemicSjogren's Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWashington University
China Registration ClassN/A

Develop Information

Active CompaniesResolve Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Sjogren's Syndrome
Inactive IndicationsLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A